Providence Therapeutics Holdings Inc: PTX-COVID19-B

Providence Therapeutics Holdings Inc: PTX-COVID19-B

Vaccine Type: RNA

About Trial Phases

Phase 1: 1 Trial

PRO-CL-001, NCT04765436
Canada

Phase 2: 0 Trials

There are no trials for this phase.

Phase 3: 0 Trials

There are no trials for this phase.

Approvals

This vaccine is not yet approved.

Registered Trials

PRO-CL-001, NCT04765436
Phase 1
Canada
Total Enrollment: 60
Official Trial Registration:
- PRO-CL-001(Opens in new tab/window)
- NCT04765436(Opens in new tab/window)

© 2021 McGill COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

The information provided on this site is for informational purposes only and should not be considered to be medical advice or an indication of an endorsement. All information is based on publicly available data.

Site Credits Website Feedback Form